• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by CVS Health Corporation

    5/7/24 4:47:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $CVS alert in real time by email
    FWP 1 d826150dfwp.htm FWP FWP

    Filed pursuant to Rule 433

    Free Writing Prospectus dated May 7, 2024

    Registration Statement No.: 333-272200

    CVS HEALTH CORPORATION

    Pricing Term Sheet—May 7, 2024

    $1,000,000,000 5.400% Senior Notes due 2029

    $1,000,000,000 5.550% Senior Notes due 2031

    $1,250,000,000 5.700% Senior Notes due 2034

    $750,000,000 6.000% Senior Notes due 2044

    $1,000,000,000 6.050% Senior Notes due 2054

     

    Issuer:    CVS Health Corporation (the “Issuer”)
    Description of Securities:   

    $1,000,000,000 5.400% Senior Notes due 2029 (the “2029 Notes”)

    $1,000,000,000 5.550% Senior Notes due 2031 (the “2031 Notes”)

    $1,250,000,000 5.700% Senior Notes due 2034 (the “2034 Notes”)

    $750,000,000 6.000% Senior Notes due 2044 (the “2044 Notes”)

    $1,000,000,000 6.050% Senior Notes due 2054 (the “2054 Notes” and, together with the 2029 Notes, the 2031 Notes, the 2034 Notes and the 2044 Notes, the “Notes”)

    Maturity Date:   

    June 1, 2029 for the 2029 Notes

    June 1, 2031 for the 2031 Notes

    June 1, 2034 for the 2034 Notes

    June 1, 2044 for the 2044 Notes

    June 1, 2054 for the 2054 Notes

    Settlement Date:    May 9, 2024 (T+2)
    Issue Price:   

    99.903% of principal amount for the 2029 Notes

    99.926% of principal amount for the 2031 Notes

    99.926% of principal amount for the 2034 Notes

    99.395% of principal amount for the 2044 Notes

    99.350% of principal amount for the 2054 Notes

    Coupon:   

    5.400% for the 2029 Notes

    5.550% for the 2031 Notes

    5.700% for the 2034 Notes

    6.000% for the 2044 Notes

    6.050% for the 2054 Notes

    Benchmark Treasury:   

    2029 Notes: 4.625% UST due April 30, 2029

    2031 Notes: 4.625% UST due April 30, 2031

    2034 Notes: 4.000% UST due February 15, 2034

    2044 Notes: 4.500% UST due February 15, 2044

    2054 Notes: 4.750% UST due November 15, 2053


    Benchmark Treasury Price and Yield:   

    2029 Notes: 100-213⁄4; 4.471%

    2031 Notes: 100-31; 4.462%

    2034 Notes: 96-12+; 4.459%

    2044 Notes: 97-13; 4.702%

    2054 Notes: 102-14+; 4.597%

    Spread to Benchmark Treasury:   

    2029 Notes: +95 basis points (0.95%)

    2031 Notes: +110 basis points (1.10%)

    2034 Notes: +125 basis points (1.25%)

    2044 Notes: +135 basis points (1.35%)

    2054 Notes: +150 basis points (1.50%)

    Yield to Maturity:   

    2029 Notes: 5.421%

    2031 Notes: 5.562%

    2034 Notes: 5.709%

    2044 Notes: 6.052%

    2054 Notes: 6.097%

    Interest Payment Dates:   

    2029 Notes: Semiannually on June 1 and December 1, commencing on December 1, 2024

    2031 Notes: Semiannually on June 1 and December 1, commencing on December 1, 2024

    2034 Notes: Semiannually on June 1 and December 1, commencing on December 1, 2024

    2044 Notes: Semiannually on June 1 and December 1, commencing on December 1, 2024

    2054 Notes: Semiannually on June 1 and December 1, commencing on December 1, 2024

    Record Dates:   

    2029 Notes: May 15 and November 15

    2031 Notes: May 15 and November 15

    2034 Notes: May 15 and November 15

    2044 Notes: May 15 and November 15

    2054 Notes: May 15 and November 15

     

    2


    Optional Redemption Provisions:   

    2029 Notes: Prior to May 1, 2029 (one month prior to the maturity date), make-whole call at any time at the greater of 100% or discounted present value at Treasury Yield plus 15 basis points. On or after May 1, 2029, redeemable at a redemption price equal to 100% of the aggregate principal amount of the Notes being redeemed.

     

    2031 Notes: Prior to April 1, 2031 (two months prior to the maturity date), make-whole call at any time at the greater of 100% or discounted present value at Treasury Yield plus 20 basis points. On or after April 1, 2031, redeemable at a redemption price equal to 100% of the aggregate principal amount of the Notes being redeemed.

     

    2034 Notes: Prior to March 1, 2034 (three months prior to the maturity date), make-whole call at any time at the greater of 100% or discounted present value at Treasury Yield plus 20 basis points. On or after March 1, 2034, redeemable at a redemption price equal to 100% of the aggregate principal amount of the Notes being redeemed.

     

    2044 Notes: Prior to December 1, 2043 (six months prior to the maturity date), make-whole call at any time at the greater of 100% or discounted present value at Treasury Yield plus 25 basis points. On or after December 1, 2043, redeemable at a redemption price equal to 100% of the aggregate principal amount of the Notes being redeemed.

     

    2054 Notes: Prior to December 1, 2053 (six months prior to the maturity date), make-whole call at any time at the greater of 100% or discounted present value at Treasury Yield plus 25 basis points. On or after December 1, 2053, redeemable at a redemption price equal to 100% of the aggregate principal amount of the Notes being redeemed.

    Change of Control:    Upon certain change of control events, the Issuer will be required to make an offer to purchase the Notes in cash at a price equal to 101% of their aggregate principal amount.
    Joint Book-Running Managers:   

    BOFA SECURITIES, INC.

    BARCLAYS CAPITAL INC.

    GOLDMAN SACHS & CO. LLC

    J.P. MORGAN SECURITIES LLC

    WELLS FARGO SECURITIES, LLC

    Co-Managers:   

    CITIGROUP GLOBAL MARKETS INC.

    MIZUHO SECURITIES USA LLC

    RBC CAPITAL MARKETS, LLC

    TRUIST SECURITIES, INC.

    UBS SECURITIES LLC

    U.S. BANCORP INVESTMENTS, INC.

    BNY MELLON CAPITAL MARKETS, LLC

    FIFTH THIRD SECURITIES, INC.

    MORGAN STANLEY & CO. LLC

    PNC CAPITAL MARKETS LLC

    SMBC NIKKO SECURITIES AMERICA, INC.

    ICBC STANDARD BANK PLC1

    KEYBANC CAPITAL MARKETS INC.

    LOOP CAPITAL MARKETS LLC

    TD SECURITIES (USA) LLC

    AMERICAN VETERANS GROUP, PBC

    MFR SECURITIES, INC.

     

    3


    CUSIP Number:   

    2029 Notes: 126650EB2

    2031 Notes: 126650EC0

    2034 Notes: 126650ED8

    2044 Notes: 126650EE6

    2054 Notes: 126650EF3

    Ratings*:    Baa2 (Moody’s) / BBB (S&P)

     

    *

    Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

    1 

    ICBC Standard Bank Plc is restricted in its U.S. securities dealings under the United States Bank Holding Company Act and may not underwrite, subscribe, agree to purchase or procure purchasers to purchase notes that are offered or sold in the United States. Accordingly, ICBC Standard Bank Plc shall not be obligated to, and shall not, underwrite, subscribe, agree to purchase or procure purchasers to purchase notes that may be offered or sold by other underwriters in the United States. ICBC Standard Bank Plc shall offer and sell the Notes constituting part of its allotment solely outside the United States.

    Changes to Preliminary Prospectus Supplement

    Other Relationships

    The following paragraph shall replace the second paragraph under the heading “Underwriting—Other Relationships”

    in the Preliminary Prospectus Supplement:

    In the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. Certain of the underwriters and their affiliates are holders of our senior notes that mature in 2024 and as a result, may receive a portion of the proceeds of the offering. If any of the underwriters or their affiliates have a lending relationship with us, certain of those underwriters or their affiliates routinely hedge, and certain other of those underwriters or their affiliates may hedge, their credit exposure to us consistent with their customary risk management policies. Typically, these underwriters and their affiliates would hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities, including potentially the notes offered hereby. Any such credit default swaps or short positions could adversely affect future trading prices of the notes offered hereby. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. An affiliate of one of the underwriters, BNY Mellon Capital Markets, LLC, is acting as Trustee, Registrar and Paying Agent in the offering.

     

     

    Capitalized terms used but not defined herein have the meanings given to them in the Preliminary Prospectus Supplement.

     

    4


    The Issuer has filed a registration statement (including a prospectus and preliminary prospectus supplement) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus and preliminary prospectus supplement in that registration statement, and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain a copy of the prospectus and the preliminary prospectus supplement from BofA Securities, Inc. by calling 1-800-294-1322 or emailing [email protected], Barclays Capital Inc. by calling toll-free 1-888-603-5847, Goldman Sachs & Co. LLC by calling 1-866-471-2526, J.P. Morgan Securities LLC by calling collect at 1-212-834-4533 and Wells Fargo Securities, LLC by calling toll-free 1-800-645-3751 or emailing [email protected].

    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.

     

    5

    Get the next $CVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVS

    DatePrice TargetRatingAnalyst
    10/14/2025$91.00Buy
    Goldman
    8/18/2025$79.00Neutral → Buy
    UBS
    8/14/2025$82.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    2/12/2025Neutral → Overweight
    Cantor Fitzgerald
    1/30/2025Hold → Buy
    Edward Jones
    12/3/2024$66.00Hold → Buy
    Deutsche Bank
    11/18/2024$60.00 → $66.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on CVS Health with a new price target

    Goldman initiated coverage of CVS Health with a rating of Buy and set a new price target of $91.00

    10/14/25 8:48:20 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health upgraded by UBS with a new price target

    UBS upgraded CVS Health from Neutral to Buy and set a new price target of $79.00

    8/18/25 8:45:28 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded CVS Health from Neutral to Outperform and set a new price target of $82.00

    8/14/25 8:02:24 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    SEC Filings

    View All

    SEC Form 13F-HR filed by CVS Health Corporation

    13F-HR - CVS HEALTH Corp (0000064803) (Filer)

    2/13/26 4:07:56 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 10-K filed by CVS Health Corporation

    10-K - CVS HEALTH Corp (0000064803) (Filer)

    2/10/26 6:36:59 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    2/10/26 6:31:12 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVS Pharmacy Partners with U.S. Soccer Federation and National Women's Soccer League to Promote Community Health and Wellness

    Building on its relationship with the Washington Spirit, CVS expands its commitment to soccer through a new multi-year sponsorship with the league and federation, which includes a national community field investment and partnering with the Kansas City Current and Seattle Reign FCWOONSOCKET, R.I., Feb. 19, 2026 /PRNewswire/ -- CVS Pharmacy® has furthered its commitment to improving community health by becoming an Official Health and Wellness Partner of the U.S. Soccer Federation (USSF) and the National Women's Soccer League (NWSL) and is backing that sponsorship with a multi-year investment to develop community multi‑use soccer fields in select markets across the country.

    2/19/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Announces $5 Million Scholarship Program to Support Future Pharmacists in Louisiana

    Investment aims to strengthen the pharmacy workforce and expand access to care across the stateBATON ROUGE, La., Feb. 18, 2026 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced the launch of a new $5 million scholarship program designed to support aspiring pharmacists in the state of Louisiana. The initiative will provide financial assistance to students pursuing their Doctor of Pharmacy (PharmD) degree at either Xavier University of Louisiana or the University of Louisiana at Monroe. This initiative is part of CVS Health's broader commitment to advancing health equity, exp

    2/18/26 8:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Fourth Quarter Highlights Total revenues increased to $105.7 billion, up 8.2% compared to prior yearGAAP diluted EPS of $2.30 and Adjusted EPS of $1.09Full-Year Highlights Total revenues increased to a record high $402.1 billion, up 7.8% compared to prior yearGAAP diluted EPS of $1.39 and Adjusted EPS of $6.75Generated cash flow from operations of $10.6 billionOperational Highlights CVS Pharmacy® successfully completed the transition to cost-based reimbursement across its Commercial, Third-Party Discount, Medicare and Medicaid businesses.Aetna® continues to improve the experience for health care professionals and their patients, approving more than 95% of all eligible prior authorizations wi

    2/10/26 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Group President Shah Prem S covered exercise/tax liability with 247 shares, decreasing direct ownership by 0.40% to 61,509 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/5/26 6:23:10 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SVP, Cont & Chief Acct Officer Clark James David covered exercise/tax liability with 220 shares, decreasing direct ownership by 0.89% to 24,401 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    12/2/25 6:03:33 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/13/24 5:02:40 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/9/23 11:16:32 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Leadership Updates

    Live Leadership Updates

    View All

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Aetna 2026 Medicare Advantage plans deliver access to affordable, personalized care

    Providing access to affordable care $0 copays on Tier 1 drugs & covered vaccines at in-network pharmacies1, $0 copay for colonoscopies and mammograms at in-network providers$0 copay for annual Healthy Home Visit from a licensed Signify Health clinicianContinued investment in technology, tools and teams that support our members Commitment to supporting unique member needs — those living with chronic conditions and individuals dually eligible for both Medicare and MedicaidLeveraging the strength of the CVS Health family of companies to deliver differentiated member experiencesWOONSOCKET, R.I., Oct. 1, 2025 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), today announced our 2026 Medi

    10/1/25 7:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer

    WOONSOCKET, R.I., April 8, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced two leadership updates. Brian Newman has been named executive vice president and chief financial officer designate, effective April 21. He will succeed current chief financial officer, Tom Cowhey, who will transition to serve as a strategic advisor to president and chief executive officer David Joyner, effective May 12.Amy Compton-Phillips, M.D., is the company's new executive vice president and chief medical officer, effective May 19, also reporting to David Joyner.Based on year-to-date res

    4/8/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Financials

    Live finance-specific insights

    View All

    CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Fourth Quarter Highlights Total revenues increased to $105.7 billion, up 8.2% compared to prior yearGAAP diluted EPS of $2.30 and Adjusted EPS of $1.09Full-Year Highlights Total revenues increased to a record high $402.1 billion, up 7.8% compared to prior yearGAAP diluted EPS of $1.39 and Adjusted EPS of $6.75Generated cash flow from operations of $10.6 billionOperational Highlights CVS Pharmacy® successfully completed the transition to cost-based reimbursement across its Commercial, Third-Party Discount, Medicare and Medicaid businesses.Aetna® continues to improve the experience for health care professionals and their patients, approving more than 95% of all eligible prior authorizations wi

    2/10/26 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health to hold fourth quarter and full year 2025 earnings conference call

    WOONSOCKET, R.I., Jan. 15, 2026 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Tuesday, February 10th, 2026, at 8:00 a.m. ET to discuss fourth quarter and full year 2025 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of S

    1/15/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health to hold fourth quarter and full year 2025 earnings conference call

    WOONSOCKET, R.I., Jan. 9, 2026 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Wednesday, February 11th, 2026, at 8:00 a.m. ET to discuss fourth quarter and full year 2025 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of

    1/9/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples